[Effect of 1 month's treatment with Bezalip on the serum lipids and lipoproteins of patients with different types of hyperlipoproteinemias].
The effect of one-month bezalip (600 mg daily) outpatient department treatment was studied on serum lipids and lipoproteins of 34 patients (31 males and 3 females), aged from 30 to 60 with various types primary HLP (IIA, IIB, IV and V). After the treatment, it was established that tendency to malization of the increased concentrations of triglycerides (Tg) and cholesterol (Chol) was changed. The drug has a stronger effect on triglyceride component of serum VIDLP and LDLP as compared with the corresponding cholesterol one, due to which its treatment is with better effect in IIB, IV and V type HLP. The decrease of cholesterol concentration in the separate types HLP differs in size and mode of induction. It is stronger in the mixed types HLP (II phi and V) and is due to decreased cholesterol content of LDLP and VLDLP, whereas in IIb type HLP - the serum concentrations of total Chol was decreased as well as of LDLP-Chol with a parallel increase of the levels of LVDLP-Chol and VLDLP-Tg. In IIA and V type HLP, serum concentration of HDLP-Chol is increased but insignificantly. Bezalip treatment changes the interlipoprotein index Ka (total Chol-HDLP-Chol/HDLP-Chol) in a favourable direction as regards the atherogenic risk, in all types HLP studied.
D000328:Adult; D000553:Ambulatory Care; D001629:Bezafibrate / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D001629:Bezafibrate
Vliianie na ednomesechno lechenie s Bezalip vŭrkhu serumnite lipidi i lipoproteini pri bolni s razlichni tipove khiperlipoproteinemii.